Can I Take Vitamin D with Cialis (Tadalafil)?

The Short Answer: No Clinically Significant Interaction Exists

Vitamin D and tadalafil do not share a metabolic enzyme, a plasma protein competition site, or a receptor that would produce a harmful interaction. Standard drug-interaction databases, including the FDA's drug interaction guidance framework and published PDE5-inhibitor prescribing data, list no contraindication between vitamin D supplementation and tadalafil [1][2].

The topic is worth examining carefully. Both agents affect vascular endothelium. Both influence nitric oxide signaling to varying degrees. Understanding how each works clarifies why they can be used together and may even complement each other in men with underlying deficiency.

How Tadalafil Works

Tadalafil inhibits phosphodiesterase type 5 (PDE5), preventing the breakdown of cyclic guanosine monophosphate (cGMP). Elevated cGMP causes smooth muscle relaxation in penile and prostatic tissue, increasing blood flow [1]. The drug is metabolized almost exclusively by hepatic CYP3A4, with a half-life of approximately 17.5 hours, which is substantially longer than sildenafil's 4-hour half-life [3].

How Vitamin D Is Metabolized

Vitamin D3 (cholecalciferol), whether from sunlight or supplements, is hydroxylated in the liver to 25-hydroxyvitamin D (25-OH D) by CYP2R1 and CYP27A1, then converted in the kidney to the active form 1,25-dihydroxyvitamin D (calcitriol) by CYP27B1. Catabolism occurs via CYP24A1 [4]. None of these enzymes overlap with CYP3A4, which is the enzyme responsible for tadalafil clearance.

Because the enzymatic pathways are completely separate, vitamin D at any standard supplemental dose does not accelerate or inhibit tadalafil metabolism [4][5].

Pharmacokinetic Profile: Why the Enzymes Don't Compete

Pharmacokinetic interactions occur when one substance changes the absorption, distribution, metabolism, or elimination of another. For two agents to interact pharmacokinetically, they typically need to share a CYP enzyme, a plasma protein binding site, or a transporter such as P-glycoprotein.

CYP3A4 and Vitamin D

Tadalafil's package insert identifies CYP3A4 inhibitors (such as ketoconazole and ritonavir) and inducers (such as rifampin) as agents that substantially change tadalafil plasma exposure [1]. Vitamin D and its active metabolites do not meaningfully inhibit or induce CYP3A4 at physiological or supplemental concentrations [5][6].

A 2013 review in the British Journal of Clinical Pharmacology documented that even pharmacological doses of calcitriol do not produce CYP3A4 inhibition sufficient to alter co-administered drug levels [6]. This means a man taking 5,000 IU of vitamin D3 daily will not experience a change in how quickly his body clears a 5 mg tadalafil dose.

Protein Binding

Tadalafil is approximately 94% protein-bound in plasma, primarily to albumin and alpha-1-acid glycoprotein [1]. Vitamin D metabolites bind to vitamin D-binding protein (DBP), a separate carrier. Competition for albumin is theoretically possible at extremely high drug concentrations but has not been demonstrated clinically for this pairing [7].

Absorption

Tadalafil absorption is not significantly affected by food or calcium-containing supplements [1]. Vitamin D3 is fat-soluble and best absorbed with a fatty meal, but this timing consideration is independent of tadalafil intake [8].

Pharmacodynamic Considerations: Shared Cardiovascular Pathways

Pharmacodynamic interactions involve two substances acting on the same biological target, producing either additive or opposing effects. Here, the relationship between vitamin D and tadalafil is more interesting because both agents influence endothelial function and nitric oxide bioavailability.

Vitamin D and Endothelial Nitric Oxide

The vitamin D receptor (VDR) is expressed in vascular smooth muscle and endothelial cells. Calcitriol upregulates endothelial nitric oxide synthase (eNOS) gene expression in cultured human endothelial cells, an effect demonstrated in a study published in Circulation [9]. Since tadalafil's mechanism depends on the nitric oxide/cGMP pathway being functional, adequate vitamin D status may support the upstream supply of nitric oxide that tadalafil amplifies downstream.

Vitamin D Deficiency and Erectile Dysfunction

A cross-sectional analysis in the Journal of Sexual Medicine (N=3,390) found that men with severe vitamin D deficiency (25-OH D <10 ng/mL) had a 32% higher prevalence of erectile dysfunction compared with men with sufficient levels (>30 ng/mL), after adjusting for age, BMI, hypertension, and diabetes [10]. A 2020 meta-analysis in Andrology pooled data from 7 observational studies (N=6,892) and reported a statistically significant association between low 25-OH D and ED (OR 1.42, 95% CI 1.18-1.70, P<0.001) [11].

These findings suggest that correcting deficiency may improve the endothelial environment in which tadalafil acts, though no head-to-head randomized trial has tested vitamin D supplementation as an adjunct to tadalafil therapy specifically.

Blood Pressure Effects

Tadalafil produces mild vasodilation and can lower systolic blood pressure by 5-8 mmHg in some patients [1]. High-dose vitamin D3 in deficient individuals may modestly reduce systolic blood pressure by approximately 3-4 mmHg, based on a 2014 Cochrane review of 46 trials [12]. The additive blood-pressure-lowering effect of the combination is small and unlikely to be clinically significant in normotensive men. Men already on antihypertensive therapy should be aware that tadalafil's package insert warns specifically against combining it with alpha-blockers or nitrates, not with vitamin D [1].

Vitamin D Deficiency Is Common in Men Taking Tadalafil

NHANES 2001-2006 data show that 41.6% of U.S. Adults have 25-OH D below 20 ng/mL, the threshold the Endocrine Society considers deficient [13]. Men with type 2 diabetes, obesity, or cardiovascular risk factors (the very populations most likely to have ED) show even higher deficiency rates. A study in Diabetes Care reported that 61% of men with type 2 diabetes had 25-OH D below 20 ng/mL [14].

Given this prevalence, a treating clinician has good reason to check a 25-OH D level in any man presenting for ED evaluation, independent of his tadalafil prescription. Treating the deficiency addresses a modifiable cardiovascular risk factor alongside the symptomatic treatment of ED.

Recommended Testing

The Endocrine Society's 2011 clinical practice guideline recommends testing 25-OH D in patients at risk for deficiency, including those with obesity, malabsorption syndromes, limited sun exposure, or darker skin pigmentation [13]. A serum 25-OH D level is the accepted clinical measure.

Repletion Targets

The Endocrine Society defines sufficiency as 25-OH D >30 ng/mL and recommends 1,500-2,000 IU/day for adults at risk of deficiency, with therapeutic doses of 50,000 IU weekly for 8 weeks used to correct established deficiency [13]. These doses are not affected by, and do not affect, concurrent tadalafil therapy.

Safety of High-Dose Vitamin D Alongside Tadalafil

The principal risk of vitamin D supplementation at high doses (consistently above 10,000 IU/day) is hypercalcemia, not a drug interaction with tadalafil. Hypercalcemia can impair smooth muscle relaxation and vascular function, which could theoretically reduce any benefit of either agent on erectile function [15].

Hypercalcemia Threshold

Vitamin D toxicity with serum 25-OH D above 150 ng/mL causes elevated serum calcium, which can produce nausea, polyuria, and, in severe cases, cardiac arrhythmia [15]. Standard supplemental doses of 1,000-4,000 IU/day do not produce toxicity in adults with normal renal function [13].

Calcium and Smooth Muscle

Calcitriol at supraphysiologic concentrations promotes calcium influx in vascular smooth muscle, which could theoretically oppose the vasodilatory mechanism of tadalafil [9]. This effect has not been observed at clinical supplement doses and is not a reason to avoid the combination at standard intakes.

Renal Function Considerations

Men with chronic kidney disease (CKD) stages 3-5 have impaired CYP27B1 activity and cannot efficiently convert 25-OH D to calcitriol. These patients often require activated vitamin D analogs such as calcitriol or paricalcitol. Tadalafil prescribing in CKD requires dose adjustment, and a nephrologist should supervise both the renal vitamin D analog and the tadalafil dose in this population [1][16].

Practical Dosing and Timing Guidance

No dose-separation window is required between vitamin D and tadalafil. The two can be taken at the same time of day without concern about pharmacokinetic interference.

Daily Tadalafil Users

Men on 5 mg tadalafil daily for ED or BPH can take their vitamin D supplement at any time, with or without the tadalafil dose. Taking vitamin D with the largest meal of the day improves fat-soluble absorption by up to 50% compared with fasting intake, based on a pharmacokinetic study in The Journal of Bone and Mineral Research [8].

On-Demand Tadalafil Users

Men who take 10 mg or 20 mg tadalafil on-demand (30 minutes to 12 hours before sexual activity) should continue their regular daily vitamin D supplement without modification. On-demand tadalafil pharmacokinetics are not altered by vitamin D status [1].

Supplement Form

Vitamin D3 (cholecalciferol) raises serum 25-OH D more effectively than D2 (ergocalciferol) at equivalent doses. A 2012 meta-analysis in the American Journal of Clinical Nutrition (N=1,176 participants across 7 RCTs) found D3 was approximately 87% more potent than D2 in raising and sustaining 25-OH D levels [17]. D3 is the preferred form for supplementation in men with ED who are also taking tadalafil.

What the FDA Label and Drug Interaction Databases Say

The FDA-approved prescribing information for tadalafil (Cialis) does not list vitamin D among its drug interactions [1]. The label's interaction section focuses on CYP3A4 modulators, nitrates, alpha-blockers, antihypertensives, and alcohol.

The Natural Medicines Comprehensive Database (cited by Mayo Clinic's drug interaction checker) rates the vitamin D and tadalafil combination as having no known interaction. The American College of Cardiology's guidance on PDE5 inhibitors and cardiovascular risk also does not flag vitamin D as a concern [18].

Prescribers reviewing this combination can be reassured that no regulatory agency or major clinical database has identified a harmful interaction.

Monitoring Recommendations for Men on Both Agents

Baseline Labs Before Starting

Before initiating tadalafil in a man with ED, clinicians commonly check fasting glucose, HbA1c, lipid panel, testosterone, and blood pressure. Adding a 25-OH D level to this panel costs little and identifies a highly prevalent, correctable deficiency [13][14].

Follow-Up for Vitamin D Repletion

After starting vitamin D supplementation at therapeutic doses (50,000 IU weekly D2 or D3), recheck 25-OH D in 8-12 weeks to confirm levels have reached 30-50 ng/mL. Serum calcium should be checked in patients on doses above 4,000 IU/day or in those with granulomatous disease or primary hyperparathyroidism, where vitamin D sensitivity is increased [13][15].

No Tadalafil Dose Adjustment Needed

Because vitamin D does not alter CYP3A4 activity at supplement doses, no adjustment to tadalafil dose is indicated when starting or stopping vitamin D supplementation [1][5][6].

Clinician and Guideline Perspectives

The Endocrine Society's 2011 clinical practice guideline on vitamin D states: "We suggest that all adults who are vitamin D deficient be treated with 50,000 IU of vitamin D2 or vitamin D3 once a week for 8 weeks or its equivalent of 6,000 IU of vitamin D2 or vitamin D3 daily to achieve a blood level of 25(OH)D above 30 ng/mL, followed by maintenance therapy of 1,500-2,000 IU/day" [13].

The American Urological Association's 2018 guideline on erectile dysfunction emphasizes that modifiable cardiovascular risk factors should be addressed alongside PDE5 inhibitor therapy, framing ED as a potential early marker of systemic vascular disease [19]. Vitamin D deficiency is an independent cardiovascular risk factor in multiple prospective cohort studies, including the LURIC cohort (N=3,258), where 25-OH D below 10 ng/mL predicted all-cause mortality with a hazard ratio of 2.08 (95% CI 1.60-2.70) over 7.7 years of follow-up [20].

Addressing vitamin D status in men with ED fits squarely within the AUA's recommendation to treat the whole cardiovascular risk profile, not just the symptom.

Special Populations

Men with Hypogonadism on TRT

Men receiving testosterone replacement therapy alongside tadalafil sometimes also take vitamin D. Testosterone and vitamin D have a bidirectional relationship: low testosterone correlates with low 25-OH D, and supplementation in deficient men has produced modest increases in total testosterone in some trials [21]. No three-way pharmacokinetic interaction among testosterone, tadalafil, and vitamin D has been identified. Each agent uses different metabolic pathways.

Older Men (Age 65 and Above)

Aging reduces cutaneous vitamin D synthesis by approximately 75% compared with young adults, making deficiency common in this group [13]. Older men are also more likely to be on multiple antihypertensives. Since tadalafil's vasodilatory effects are additive with antihypertensives (but not with vitamin D), the relevant interaction to monitor in older men is the tadalafil-antihypertensive pairing, not the tadalafil-vitamin D pairing [1].

Men with Obesity

Vitamin D is sequestered in adipose tissue, lowering bioavailable serum 25-OH D. Obese men (BMI >30) may require 2 to 3 times the standard supplemental dose to achieve sufficiency [13]. Tadalafil pharmacokinetics are not significantly altered by obesity. Both conditions are common in men presenting for ED treatment.